POST Facilitation for Post Traumatic Stress Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Post Traumatic Stress Disorder+3 MorePOST Facilitation - Behavioral
Eligibility
65+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the effects of a Physician Orders for Scope of Treatment (POST) Facilitation in a population of older adults who qualify for it, including those with normal cognition and those with Alzheimer's Disease and related disorders.

Eligible Conditions
  • Post Traumatic Stress Disorder
  • Anxiety
  • Depression
  • Satisfaction

Treatment Effectiveness

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Assessed 12 months from the date that the patient receives POST facilitation or home safety evaluation

Month 12
Discordance between treatment preferences and treatment received 12 months after POST Facilitation
Month 3
Decision conflict
Decision quality
Effect of the intervention on psychological well-being (anxiety)
Effect of the intervention on psychological well-being (depression)
Effect of the intervention on psychological well-being (post traumatic stress)
Proportion of patients who have a completed POST form 3 months after receiving POST Facilitation
Month 12
Effect of the intervention on cost and end of life care (EOL) for patients who die within 12 months of the intervention

Trial Safety

Trial Design

1 Treatment Group

Intervention (POST Facilitation)
1 of 1

Experimental Treatment

876 Total Participants · 1 Treatment Group

Primary Treatment: POST Facilitation · No Placebo Group · N/A

Intervention (POST Facilitation)
Behavioral
Experimental Group · 1 Intervention: POST Facilitation · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: assessed 12 months from the date that the patient receives post facilitation or home safety evaluation

Who is running the clinical trial?

Regenstrief Institute, Inc.OTHER
21 Previous Clinical Trials
93,605 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,414 Previous Clinical Trials
3,483,346 Total Patients Enrolled
Indiana University HealthOTHER
26 Previous Clinical Trials
13,785 Total Patients Enrolled
Indiana UniversityLead Sponsor
876 Previous Clinical Trials
748,679 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,442 Previous Clinical Trials
24,577,402 Total Patients Enrolled
Eskenazi HealthOTHER
7 Previous Clinical Trials
898 Total Patients Enrolled
Respecting ChoicesUNKNOWN
1 Previous Clinical Trials
60 Total Patients Enrolled
Alexia M Torke, MD, MSPrincipal InvestigatorRegenstrief Institute, Indiana University
1 Previous Clinical Trials
192 Total Patients Enrolled

Eligibility Criteria

Age 65+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have end-stage renal disease.
You have a MELD index of at least 18.5.\n
Patients with an impaired performance score (greater than zero) are not eligible for this trial.
You have airflow obstruction, exacerbations, smoking and comorbidities (BARC) Index for chronic obstructive pulmonary disease (COPD): high risk group.

Who else is applying?

What state do they live in?
Indiana100.0%
What site did they apply to?
Eskenazi Health50.0%
IU Health Methodist Hospital50.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
Why did patients apply to this trial?
  • "I’ve had severe depression and BPD got many years. I’ve gone through a lot of antidepressants. I see a therapist biweekly. It seems like my cycles of depression are so severe I can’t get out of bed some days. I’ve been hospitalized 3 times in the last two years."
How many prior treatments have patients received?
3+100.0%

How responsive is this trial?

Typically responds via
Email100.0%
Most responsive sites:
  1. IU Health Methodist Hospital: < 24 hours
Average response time
  • < 1 Day